Vascular smooth muscle insulin resistance, but not hypertrophic signaling, is independent of angiotensin II-induced IRS-1 phosphorylation by JNK

American Journal of Physiology - Cell Physiology

Volumn 301, Issue 6, 2011, Pages

  Hitomi, Hirofumi ^a   Mehta, Puja K ^a   Taniyama, Yoshihiro ^a   Lassègue, Bernard ^a   Seidel Rogol, Bonnie ^a   Martin, Alejandra San ^a   Griendling, Kathy K ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

C Jun NH 2 terminal kinase; Insulin receptor substrate degradation; Insulin receptor substrate 1; Serine phosphorylation in insulin signaling

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN II; COLLAGEN TYPE 1; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; MESSENGER RNA; PROTEIN KINASE B; SERINE; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; CELL CULTURE; COLLAGEN SYNTHESIS; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENETIC TRANSFECTION; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; INSULIN METABOLISM; INSULIN RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; SMOOTH MUSCLE FIBER; SYSTEMATIC REVIEW; VASCULAR SMOOTH MUSCLE;

ACTINS; ANGIOTENSIN II; ANIMALS; BLOTTING, WESTERN; ENZYME INHIBITORS; HYPERTROPHY; IMMUNOPRECIPITATION; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MUSCLE, SMOOTH, VASCULAR; PHOSPHORYLATION; RATS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 82455219478     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00017.2011     Document Type: Article

References (58)

1. Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 275: 9047-9054, 2000.
2. Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem 277: 1531-1537, 2002.
3. Alessi DR, Cohen P. Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev 8: 55-62, 1998.
4. Andreozzi F, Laratta E, Sciacqua A, Perticone F, Sesti G. Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in human umbilical vein endothelial cells. Circ Res 94: 1211-1218, 2004.
5. Bogoyevitch MA, Kobe B. Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. Microbiol Mol Biol Rev 70: 1061-1095, 2006.
6. Bouzakri K, Roques M, Gual P, Espinosa S, Guebre-Egziabher F, Riou JP, Laville M, Le Marchand-Brustel Y. Tanti JF, Vidal H. Reduced activation of phosphatidylinositol-3 kinase and increased serine 636 phosphorylation of insulin receptor substrate-1 in primary culture of skeletal muscle cells from patients with type 2 diabetes. Diabetes 52: 1319-1325, 2003.
7. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001.
8. Clark SF, Martin S, Carozzi AJ, Hill MM, James DE. Intracellular localization of phosphatidylinositide 3-kinase and insulin receptor substrate-1 in adipocytes: potential involvement of a membrane skeleton. J Cell Biol 140: 1211-1225, 1998.
9. Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 68: 450-456, 1991.
10. Danielsson A, Nystrom FH, Stralfors P. Phosphorylation of IRS1 at serine 307 and serine 312 in response to insulin in human adipocytes. Biochem Biophys Res Commun 342: 1183-1187, 2006.
11. Diah S, Zhang GX, Nagai Y, Zhang W, Gang L, Kimura S, Hamid MR, Tamiya T, Nishiyama A, Hitomi H. Aldosterone induces myofibroblastic transdifferentiation and collagen gene expression through the Rho-kinase dependent signaling pathway in rat mesangial cells. Exp Cell Res 314: 3654-3662, 2008.
12. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 77: 863-868, 1995.
13. Draznin B. Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85alpha: the two sides of a coin. Diabetes 55: 2392-2397, 2006.
14. Egawa K, Sharma PM, Nakashima N, Huang Y, Huver E, Boss GR, Olefsky JM. Membrane-targeted phosphatidylinositol 3-kinase mimics insulin actions and induces a state of cellular insulin resistance. J Biol Chem 274: 14306-14314, 1999.
15. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 100: 2158-2169, 1997.
16. Furukawa N, Ongusaha P, Jahng WJ, Araki K, Choi CS, Kim HJ, Lee YH, Kaibuchi K, Kahn BB, Masuzaki H, Kim JK, Lee SW, Kim YB. Role of Rho-kinase in regulation of insulin action and glucose homeostasis. Cell Metab 2: 119-129, 2005.
17. Garcia-Cazarin ML, Smith JL, Clair DK, Piascik MT. The alpha1Dadrenergic receptor induces vascular smooth muscle apoptosis via a p53-dependent mechanism. Mol Pharmacol 74: 1000-1007, 2008.
18. Greene MW, Sakaue H, Wang L, Alessi DR, Roth RA. Modulation of insulin-stimulated degradation of human insulin receptor substrate-1 by serine 312 phosphorylation. J Biol Chem 278: 8199-8211, 2003.
19. Griendling KK, Taubman MB, Akers M, Mendlowitz M, Alexander RW. Characterization of phosphatidylinositol-specific phospholipase C from cultured vascular smooth muscle cells. J Biol Chem 266: 15498-15504, 1991.
20. Hilder TL, Tou JC, Grindeland RE, Wade CE, Graves LM. Phosphorylation of insulin receptor substrate-1 serine 307 correlates with JNK activity in atrophic skeletal muscle. FEBS Lett 553: 63-67, 2003.
21. Hitomi H, Kaifu K, Fujita Y, Sofue T, Nakano D, Moriwaki K, Hara T, Kiyomoto H, Kohno M, Kobori H, Nishiyama A. Angiotensin II shifts insulin signaling into vascular remodeling from glucose metabolism in vascular smooth muscle cells. Am J Hypertens 24: 1149-1155, 2011.
22. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha-and obesity-induced insulin resistance. Science 271: 665-668, 1996.
23. Huang XC, Deng T, Sumners C. Angiotensin II stimulates activation of Fos-regulating kinase and c-Jun NH2-terminal kinase in neuronal cultures from rat brain. Endocrinology 139: 245-251, 1998.
24. Iimura O, Shimamoto K, Matsuda K, Masuda A, Takizawa H, Higashiura K, Miyazaki Y, Hirata A, Ura N, Nakagawa M. Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives. Am J Hypertens 8: 353-357, 1995.
25. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 91: 2268-2274, 1993.
26. Iyer SN, Katovich MJ. Effect of acute and chronic losartan treatment on glucose tolerance and insulin sensitivity in fructose-fed rats. Am J Hypertens 9: 662-668, 1996.
27. Kaburagi Y, Satoh S, Yamamoto-Honda R, Ito T, Ueki K, Akanuma Y, Sekihara H, Kimura S, Kadowaki T. Insulin-independent and wortmannin-resistant targeting of IRS-3 to the plasma membrane via its pleckstrin homology domain mediates a different interaction with the insulin receptor from that of IRS-1. Diabetologia 44: 992-1004, 2001.
28. Kasuga M, Zick Y, Blithe DL, Crettaz M, Kahn CR. Insulin stimulates tyrosine phosphorylation of the insulin receptor in a cell-free system. Nature 298: 667-669, 1982.
29. Kim F, Tysseling KA, Rice J, Gallis B, Haji L, Giachelli CM, Raines EW, Corson MA, Schwartz MW. Activation of IKKbeta by glucose is necessary and sufficient to impair insulin signaling and nitric oxide production in endothelial cells. J Mol Cell Cardiol 39: 327-334, 2005.
30. Kim YK, Lee MS, Son SM, Kim IJ, Lee WS, Rhim BY, Hong KW, Kim CD. Vascular NADH oxidase is involved in impaired endotheliumdependent vasodilation in OLETF rats, a model of type 2 diabetes. Diabetes 51: 522-527, 2002.
31. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science 307: 384-387, 2005.
32. Mothe I, Van Obberghen E. Phosphorylation of insulin receptor substrate-1 on multiple serine residues, 612, 632, 662, and 731, modulates insulin action. J Biol Chem 271: 11222-11227, 1996.
33. Munoz MC, Argentino DP, Dominici FP, Turyn D, Toblli JE. Irbesartan restores the in-vivo insulin signaling pathway leading to Akt activation in obese Zucker rats. J Hypertens 24: 1607-1617, 2006.
34. Mussig K, Fiedler H, Staiger H, Weigert C, Lehmann R, Schleicher ED, Haring HU. Insulin-induced stimulation of JNK and the PI 3-kinase/ mTOR pathway leads to phosphorylation of serine 318 of IRS-1 in C2C12 myotubes. Biochem Biophys Res Commun 335: 819-825, 2005.
35. Nawano M, Anai M, Funaki M, Kobayashi H, Kanda A, Fukushima Y, Inukai K, Ogihara T, Sakoda H, Onishi Y, Kikuchi M, Yazaki Y, Oka Y, Asano T. Imidapril, an angiotensin-converting enzyme inhibitor, improves insulin sensitivity by enhancing signal transduction via insulin receptor substrate proteins and improving vascular resistance in the Zucker fatty rat. Metabolism 48: 1248-1255, 1999.
36. Ogihara T, Asano T, Ando K, Chiba Y, Sakoda H, Anai M, Shojima N, Ono H, Onishi Y, Fujishiro M, Katagiri H, Fukushima Y, Kikuchi M, Noguchi N, Aburatani H, Komuro I, Fujita T. Angiotensin IIinduced insulin resistance is associated with enhanced insulin signaling. Hypertension 40: 872-879, 2002.
37. Ozes ON, Akca H, Mayo LD, Gustin JA, Maehama T, Dixon JE, Donner DB. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Proc Natl Acad Sci USA 98: 4640-4645, 2001.
38. Pederson TM, Kramer DL, Rondinone CM. Serine/threonine phosphorylation of IRS-1 triggers its degradation: possible regulation by tyrosine phosphorylation. Diabetes 50: 24-31, 2001.
39. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40: 1286-1292, 1997.
40. Qi C, Pekala PH. Tumor necrosis factor-alpha-induced insulin resistance in adipocytes. Proc Soc Exp Biol Med 223: 128-135, 2000.
41. Rui L, Aguirre V, Kim JK, Shulman GI, Lee A, Corbould A, Dunaif A, White MF. Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J Clin Invest 107: 181-189, 2001.
42. Solinas G, Naugler W, Galimi F, Lee MS, Karin M. Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates. Proc Natl Acad Sci USA 103: 16454-16459, 2006.
43. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 97: 2601-2610, 1996.
44. Sugita H, Fujimoto M, Yasukawa T, Shimizu N, Sugita M, Yasuhara S, Martyn JA, Kaneki M. Inducible nitric-oxide synthase and NO donor induce insulin receptor substrate-1 degradation in skeletal muscle cells. J Biol Chem 280: 14203-14211, 2005.
45. Sun XJ, Rothenberg P, Kahn CR, Backer JM, Araki E, Wilden PA, Cahill DA, Goldstein BJ, White MF. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 352: 73-77, 1991.
46. Suzuki M, Shinozaki K, Kanazawa A, Hara Y, Hattori Y, Tsushima M, Harano Y. Insulin resistance as an independent risk factor for carotid wall thickening. Hypertension 28: 593-598, 1996.
47. Taniyama Y, Hitomi H, Shah A, Alexander RW, Griendling KK. Mechanisms of reactive oxygen species-dependent downregulation of insulin receptor substrate-1 by angiotensin II. Arterioscler Thromb Vasc Biol 25: 1142-1147, 2005.
48. Taniyama Y, Ushio-Fukai M, Hitomi H, Rocic P, Kingsley MJ, Pfahnl C, Weber DS, Alexander RW, Griendling KK. Role of p38 MAPK and MAPKAPK-2 in angiotensin II-induced Akt activation in vascular smooth muscle cells. Am J Physiol Cell Physiol 287: C494-C499, 2004.
49. Tanti JF, Gual P, Gremeaux T, Gonzalez T, Barres R, Le Marchand-Brustel Y. Alteration in insulin action: role of IRS-1 serine phosphorylation in the retroregulation of insulin signalling. Ann Endocrinol (Paris) 65: 43-48, 2004.
50. Tanti JF, Jager J. Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. Curr Opin Pharmacol 9: 753-762, 2009.
51. Uemura S, Matsushita H, Li W, Glassford AJ, Asagami T, Lee KH, Harrison DG, Tsao PS. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res 88: 1291-1298, 2001.
52. Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif JC. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 107: 1291-1296, 2003.
53. Wen Y, Scott S, Liu Y, Gonzales N, Nadler JL. Evidence that angiotensin II and lipoxygenase products activate c-Jun NH2-terminal kinase. Circ Res 81: 651-655, 1997.
54. Werner ED, Lee J, Hansen L, Yuan M, Shoelson SE. Insulin resistance due to phosphorylation of insulin receptor substrate-1 at serine 302. J Biol Chem 279: 35298-35305, 2004.
55. White MF. IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 283: E413-E422, 2002.
56. White MF, Shoelson SE, Keutmann H, Kahn CR. A cascade of tyrosine autophosphorylation in the beta-subunit activates the phosphotransferase of the insulin receptor. J Biol Chem 263: 2969-2980, 1988.
57. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047-1053, 2004.
58. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342: 145-153, 2000.